Spectrum Pharmaceuticals, Inc. (SPPI) Reaches $19.93 After 4.00% Up Move; 3 Analysts Covering Cedar Realty Trust, Inc. (CDR)

April 17, 2018 - By Vivian Currie

Cedar Realty Trust, Inc. (NYSE:CDR) Logo

Among 6 analysts covering Cedar Realty Trust (NYSE:CDR), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Cedar Realty Trust had 16 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Cedar Realty Trust, Inc. (NYSE:CDR) has “Hold” rating given on Wednesday, August 12 by Zacks. On Monday, November 27 the stock rating was maintained by Robert W. Baird with “Buy”. The firm earned “Buy” rating on Monday, February 12 by FBR Capital. Wunderlich upgraded the shares of CDR in report on Tuesday, May 10 to “Buy” rating. The rating was maintained by Robert W. Baird on Friday, February 9 with “Buy”. The stock of Cedar Realty Trust, Inc. (NYSE:CDR) earned “Underperform” rating by Boenning & Scattergood on Tuesday, June 28. The stock has “Outperform” rating by Robert W. Baird on Monday, March 13. The rating was maintained by Robert W. Baird with “Outperform” on Monday, February 12. On Friday, November 3 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. As per Monday, August 7, the company rating was maintained by Boenning & Scattergood. See Cedar Realty Trust, Inc. (NYSE:CDR) latest ratings:

12/02/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $7 New Target: $6 Maintain
12/02/2018 Broker: FBR Capital Rating: Buy New Target: $5.5 Maintain
09/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $6.0 Maintain
14/12/2017 Broker: Raymond James Rating: Hold
27/11/2017 Broker: Robert W. Baird Rating: Buy New Target: $7.0 Maintain
06/11/2017 Broker: FBR Capital Rating: Buy New Target: $6.5
06/11/2017 Broker: Boenning & Scattergood Rating: Sell New Target: $4.5 Maintain
03/11/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain

The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is a huge mover today! The stock increased 7.38% or $1.37 during the last trading session, reaching $19.93. About 838,759 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since April 17, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.The move comes after 9 months positive chart setup for the $2.03B company. It was reported on Apr, 17 by Barchart.com. We have $20.73 PT which if reached, will make NASDAQ:SPPI worth $81.08M more.

The stock increased 1.81% or $0.07 during the last trading session, reaching $3.94. About 137,615 shares traded. Cedar Realty Trust, Inc. (NYSE:CDR) has declined 23.11% since April 17, 2017 and is downtrending. It has underperformed by 34.66% the S&P500.

Cedar Realty Trust, Inc. is an independent equity real estate investment trust. The company has market cap of $362.71 million. The firm is primarily engaged in ownership, operation, development, and redevelopment of properties. It currently has negative earnings. It invests in the real estate markets of the United States predominantly in mid- Atlantic and Northeast coastal states.

Investors sentiment increased to 1.95 in 2017 Q4. Its up 0.62, from 1.33 in 2017Q3. It increased, as 13 investors sold Cedar Realty Trust, Inc. shares while 31 reduced holdings. 29 funds opened positions while 57 raised stakes. 80.96 million shares or 3.37% more from 78.32 million shares in 2017Q3 were reported. Ubs Asset Mgmt Americas owns 0% invested in Cedar Realty Trust, Inc. (NYSE:CDR) for 194,067 shares. California Public Employees Retirement Sys holds 0% of its portfolio in Cedar Realty Trust, Inc. (NYSE:CDR) for 274,939 shares. Amp Invsts Ltd holds 0% or 31,839 shares in its portfolio. Parallax Volatility Advisers L P reported 0% in Cedar Realty Trust, Inc. (NYSE:CDR). Ls Inv has invested 0% of its portfolio in Cedar Realty Trust, Inc. (NYSE:CDR). Brandywine Investment Mgmt stated it has 0.02% of its portfolio in Cedar Realty Trust, Inc. (NYSE:CDR). First Advsr L P has 0% invested in Cedar Realty Trust, Inc. (NYSE:CDR) for 18,928 shares. Thrivent Fin For Lutherans invested in 411,750 shares. Clearbridge Invests Ltd Liability Com holds 0% or 1,000 shares. Guggenheim Cap Limited Liability Company reported 12,678 shares stake. Oberweis Asset, Illinois-based fund reported 103,870 shares. Moreover, Amer Group Incorporated has 0% invested in Cedar Realty Trust, Inc. (NYSE:CDR). Third Avenue Management Ltd Liability Corporation owns 175,700 shares. Tower Research Limited Co (Trc) has invested 0.01% of its portfolio in Cedar Realty Trust, Inc. (NYSE:CDR). Moreover, Ny State Common Retirement Fund has 0% invested in Cedar Realty Trust, Inc. (NYSE:CDR) for 77,700 shares.

Since March 21, 2018, it had 0 insider purchases, and 13 insider sales for $6.83 million activity. Shares for $78,278 were sold by Krassner Stuart Mitchell. SHROTRIYA RAJESH C MD also sold $1.83 million worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares. Turgeon Joseph W. also sold $78,884 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Wednesday, March 28. Riga Thomas J had sold 1,948 shares worth $30,350 on Monday, April 2. GUSTAFSON KURT A sold $47,868 worth of stock or 2,640 shares.

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma has $32 highest and $8.25 lowest target. $19.46’s average target is -2.36% below currents $19.93 stock price. Spectrum Pharma had 12 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Monday, October 9 with “Buy” rating. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has “Buy” rating given on Tuesday, April 10 by FBR Capital. Zacks upgraded Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Thursday, August 27 to “Hold” rating. The company was maintained on Thursday, August 24 by Jefferies. On Thursday, November 5 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Wednesday, June 7 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating given on Wednesday, August 16 by H.C. Wainwright. The company was maintained on Friday, August 7 by RBC Capital Markets. The firm earned “Buy” rating on Friday, February 10 by Jefferies.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $2.03 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Investors sentiment decreased to 1.63 in Q4 2017. Its down 1.21, from 2.84 in 2017Q3. It dived, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported. Manufacturers Life Insurance Co The stated it has 66,341 shares or 0% of all its holdings. Rhumbline Advisers reported 210,642 shares. Proshare Lc reported 0.01% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). State Street owns 4.11 million shares or 0.01% of their US portfolio. Plante Moran Fin Advisors Limited Liability invested in 8,350 shares or 0.09% of the stock. Goldman Sachs Group Inc Inc owns 1.86M shares. Bank Of America De stated it has 415,652 shares. Moreover, First Personal Fincl Svcs has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 370 shares. Fifth Third National Bank & Trust has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Arizona-based Tci Wealth has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). 204,113 were reported by California Employees Retirement. Brown Advisory Secs Limited Company stated it has 0.09% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Nordea Investment Ab stated it has 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Leucadia National has 18,934 shares. Blackrock holds 0.01% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 15.99 million shares.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.